Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03FVS
|
||||
| Former ID |
DCL000332
|
||||
| Drug Name |
Salvicine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Cancer [ICD9: 140-229; ICD10:C00-C96] | Phase 2 | [528379] | ||
| Company |
Shanghai Institute of Materia Medica (SIMM)
|
||||
| Formula |
C20H26O4
|
||||
| Canonical SMILES |
CC1=C(C2=C(C=C1)C=C(C(=O)C2=O)C(C)C)CCC(C(C)(C)O)O
|
||||
| InChI |
1S/C20H26O4/c1-11(2)15-10-13-7-6-12(3)14(17(13)19(23)18(15)22)8-9-16(21)20(4,5)24/h6-7,10-11,16,21,24H,8-9H2,1-5H3
|
||||
| InChIKey |
NZIUPDOWWMGNCV-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | DNA topoisomerase II | Target Info | Modulator | [528379], [536485] | |
| References | |||||
| Ref 528379 | Salvicine functions as novel topoisomerase II poison by binding to ATP pocket. Mol Pharmacol. 2006 Nov;70(5):1593-601. Epub 2006 Aug 16. | ||||
| Ref 536485 | Salvicine, a novel topoisomerase II inhibitor, exerts its potent anticancer activity by ROS generation. Acta Pharmacol Sin. 2007 Sep;28(9):1460-5. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.